EMBL Keynote Lecture - Ubiquitin mediated regulation of transcription factor stability, Vishva Dixit

Value of the Information & Strength of the Argument

The value of this presentation lies in its novel mechanistic insight into acquired resistance to MAPK pathway inhibitors in melanoma. The argumentation is strong, based on a combination of clinical observations, genetic manipulation (knockouts, patient mutations), unbiased chemical screens, global proteomics, and transcriptomics. The speaker systematically demonstrates that COP1 mutations disrupt substrate binding, stabilize ETV5, and confer resistance specifically to MEK/ERK inhibitors. The use of rescue experiments (deleting ETV5) provides causal evidence. The argumentation is logical and well-supported by controls, though the work is unpublished and some aspects (like the dominant-negative effect) remain preliminary.

Scientific Rigor, Source Quality, Title Accuracy

Rigor is high: the talk includes multiple experimental approaches and controls, and the conclusions are drawn from quantitative data (growth curves, proteomics). The speaker cites several of his own published papers (e.g., Vitari et al. 2011, Suriben et al. 2015) that establish COP1’s role, and the unpublished work is presented with appropriate caution. The title accurately describes the content, focusing on ubiquitin-mediated regulation of transcription factor stability, and matches the presented material. No comments were analyzed as none were provided.

The title accurately reflects the content, focusing on ubiquitin-mediated regulation of transcription factor stability, specifically COP1 and ETV5.

7/10

Presentation by a leading researcher from Genentech, based on unpublished data with references to published work. However, the talk presents preliminary results and lacks full experimental details, so a moderate-high score is given.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 01:00Introduction and patient case with COP1 mutation leading to therapy resistance
• 06:00Description of COP1 E3 ligase complex and its role in degrading ETS transcription factors
• 12:00Experiments showing ETV5 accumulation and degradation in response to MAPK inhibitors
• 18:00Unbiased screen and proteomics identifying ETV5 as major substrate and resistance driver
• 25:00RNA-seq analysis revealing downstream targets (SLUG, MITF) and conclusion

• Human De-Etiolated-1 Regulates c-Jun by Assembling a CUL4A Ubiquitin Ligase (Wertz et al., Science 2004) — Reference [1] in description, foundational for COP1 complex
• COP1 is a Tumor Suppressor that Causes Deregulation of Proto-oncogenic ETS Transcription Factors (Vitari et al., Nature 2011) — Reference [2], establishes COP1's role in cancer
• β-cell insulin secretion requires the ubiquitin ligase COP1 (Suriben et al., Cell 2015) — Reference [3], additional COP1 function

• Vitari et al., Nature 2011 — Shows COP1 as tumor suppressor and regulates ETS factors, supporting the talk's foundational claims.
• Wertz et al., Science 2004 — Describes the COP1 complex and its regulation of c-Jun, complementary to mechanisms discussed.